Titlebook: Non-Vitamin K Antagonist Oral Anticoagulants; A Concise Guide Eduard Shantsila,Gregory YH Lip Book‘‘‘‘‘‘‘‘ 2016 The Editor(s) (if applicabl

Jackson

書目名稱Non-Vitamin K Antagonist Oral Anticoagulants影響因子(影響力)




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants影響因子(影響力)學(xué)科排名




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants網(wǎng)絡(luò)公開(kāi)度




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants被引頻次




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants被引頻次學(xué)科排名




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants年度引用




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants年度引用學(xué)科排名




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants讀者反饋




書目名稱Non-Vitamin K Antagonist Oral Anticoagulants讀者反饋學(xué)科排名

水土

http://image.papertrans.cn/n/image/667058.jpg

北京人起源

https://doi.org/10.1007/978-3-319-25460-9Atrial Fibrillation; Coagulation; Factor Xa; Thromboembolism; Stroke; Acute Coronary Syndromes

冰河期

不安

和諧

endoscopy

Salivary-Gland

反叛者

誘使

Conclusions,rillation (AF) [1] and the prevention of recurrent venous thromboembolism (VTE) [2]. These meta-analyses were the first to include data for all four NOACs studied in pivotal phase III studies for these indications.